Cargando…

In vivo production of fluorine-18 in a chicken egg tumor model of breast cancer for proton therapy range verification

Range verification of clinical protontherapy systems via positron-emission tomography (PET) is not a mature technology, suffering from two major issues: insufficient signal from low-energy protons in the Bragg peak area and biological washout of PET emitters. The use of contrast agents including (18...

Descripción completa

Detalles Bibliográficos
Autores principales: España, Samuel, Sánchez-Parcerisa, Daniel, Bragado, Paloma, Gutiérrez-Uzquiza, Álvaro, Porras, Almudena, Gutiérrez-Neira, Carolina, Espinosa, Andrea, Onecha, Víctor V., Ibáñez, Paula, Sánchez-Tembleque, Víctor, Udías, José M., Fraile, Luis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056503/
https://www.ncbi.nlm.nih.gov/pubmed/35490180
http://dx.doi.org/10.1038/s41598-022-11037-7
_version_ 1784697677364068352
author España, Samuel
Sánchez-Parcerisa, Daniel
Bragado, Paloma
Gutiérrez-Uzquiza, Álvaro
Porras, Almudena
Gutiérrez-Neira, Carolina
Espinosa, Andrea
Onecha, Víctor V.
Ibáñez, Paula
Sánchez-Tembleque, Víctor
Udías, José M.
Fraile, Luis M.
author_facet España, Samuel
Sánchez-Parcerisa, Daniel
Bragado, Paloma
Gutiérrez-Uzquiza, Álvaro
Porras, Almudena
Gutiérrez-Neira, Carolina
Espinosa, Andrea
Onecha, Víctor V.
Ibáñez, Paula
Sánchez-Tembleque, Víctor
Udías, José M.
Fraile, Luis M.
author_sort España, Samuel
collection PubMed
description Range verification of clinical protontherapy systems via positron-emission tomography (PET) is not a mature technology, suffering from two major issues: insufficient signal from low-energy protons in the Bragg peak area and biological washout of PET emitters. The use of contrast agents including (18)O, (68)Zn or (63)Cu, isotopes with a high cross section for low-energy protons in nuclear reactions producing PET emitters, has been proposed to enhance the PET signal in the last millimeters of the proton path. However, it remains a challenge to achieve sufficient concentrations of these isotopes in the target volume. Here we investigate the possibilities of (18)O-enriched water (18-W), a potential contrast agent that could be incorporated in large proportions in live tissues by replacing regular water. We hypothesize that 18-W could also mitigate the problem of biological washout, as PET ((18)F) isotopes created inside live cells would remain trapped in the form of fluoride anions (F-), allowing its signal to be detected even hours after irradiation. To test our hypothesis, we designed an experiment with two main goals: first, prove that 18-W can incorporate enough (18)O into a living organism to produce a detectable signal from (18)F after proton irradiation, and second, determine the amount of activity that remains trapped inside the cells. The experiment was performed on a chicken embryo chorioallantoic membrane tumor model of head and neck cancer. Seven eggs with visible tumors were infused with 18-W and irradiated with 8-MeV protons (range in water: 0.74 mm), equivalent to clinical protons at the end of particle range. The activity produced after irradiation was detected and quantified in a small-animal PET-CT scanner, and further studied by placing ex-vivo tumours in a gamma radiation detector. In the acquired images, specific activity of (18)F (originating from 18-W) could be detected in the tumour area of the alive chicken embryo up to 9 h after irradiation, which confirms that low-energy protons can indeed produce a detectable PET signal if a suitable contrast agent is employed. Moreover, dynamic PET studies in two of the eggs evidenced a minimal effect of biological washout, with 68% retained specific (18)F activity at 8 h after irradiation. Furthermore, ex-vivo analysis of 4 irradiated tumours showed that up to 3% of oxygen atoms in the targets were replaced by (18)O from infused 18-W, and evidenced an entrapment of 59% for specific activity of (18)F after washing, supporting our hypothesis that F- ions remain trapped within the cells. An infusion of 18-W can incorporate (18)O in animal tissues by replacing regular water inside cells, producing a PET signal when irradiated with low-energy protons that could be used for range verification in protontherapy. (18)F produced inside cells remains entrapped and suffers from minimal biological washout, allowing for a sharper localization with longer PET acquisitions. Further studies must evaluate the feasibility of this technique in dosimetric conditions closer to clinical practice, in order to define potential protocols for its use in patients.
format Online
Article
Text
id pubmed-9056503
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90565032022-05-02 In vivo production of fluorine-18 in a chicken egg tumor model of breast cancer for proton therapy range verification España, Samuel Sánchez-Parcerisa, Daniel Bragado, Paloma Gutiérrez-Uzquiza, Álvaro Porras, Almudena Gutiérrez-Neira, Carolina Espinosa, Andrea Onecha, Víctor V. Ibáñez, Paula Sánchez-Tembleque, Víctor Udías, José M. Fraile, Luis M. Sci Rep Article Range verification of clinical protontherapy systems via positron-emission tomography (PET) is not a mature technology, suffering from two major issues: insufficient signal from low-energy protons in the Bragg peak area and biological washout of PET emitters. The use of contrast agents including (18)O, (68)Zn or (63)Cu, isotopes with a high cross section for low-energy protons in nuclear reactions producing PET emitters, has been proposed to enhance the PET signal in the last millimeters of the proton path. However, it remains a challenge to achieve sufficient concentrations of these isotopes in the target volume. Here we investigate the possibilities of (18)O-enriched water (18-W), a potential contrast agent that could be incorporated in large proportions in live tissues by replacing regular water. We hypothesize that 18-W could also mitigate the problem of biological washout, as PET ((18)F) isotopes created inside live cells would remain trapped in the form of fluoride anions (F-), allowing its signal to be detected even hours after irradiation. To test our hypothesis, we designed an experiment with two main goals: first, prove that 18-W can incorporate enough (18)O into a living organism to produce a detectable signal from (18)F after proton irradiation, and second, determine the amount of activity that remains trapped inside the cells. The experiment was performed on a chicken embryo chorioallantoic membrane tumor model of head and neck cancer. Seven eggs with visible tumors were infused with 18-W and irradiated with 8-MeV protons (range in water: 0.74 mm), equivalent to clinical protons at the end of particle range. The activity produced after irradiation was detected and quantified in a small-animal PET-CT scanner, and further studied by placing ex-vivo tumours in a gamma radiation detector. In the acquired images, specific activity of (18)F (originating from 18-W) could be detected in the tumour area of the alive chicken embryo up to 9 h after irradiation, which confirms that low-energy protons can indeed produce a detectable PET signal if a suitable contrast agent is employed. Moreover, dynamic PET studies in two of the eggs evidenced a minimal effect of biological washout, with 68% retained specific (18)F activity at 8 h after irradiation. Furthermore, ex-vivo analysis of 4 irradiated tumours showed that up to 3% of oxygen atoms in the targets were replaced by (18)O from infused 18-W, and evidenced an entrapment of 59% for specific activity of (18)F after washing, supporting our hypothesis that F- ions remain trapped within the cells. An infusion of 18-W can incorporate (18)O in animal tissues by replacing regular water inside cells, producing a PET signal when irradiated with low-energy protons that could be used for range verification in protontherapy. (18)F produced inside cells remains entrapped and suffers from minimal biological washout, allowing for a sharper localization with longer PET acquisitions. Further studies must evaluate the feasibility of this technique in dosimetric conditions closer to clinical practice, in order to define potential protocols for its use in patients. Nature Publishing Group UK 2022-04-30 /pmc/articles/PMC9056503/ /pubmed/35490180 http://dx.doi.org/10.1038/s41598-022-11037-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
España, Samuel
Sánchez-Parcerisa, Daniel
Bragado, Paloma
Gutiérrez-Uzquiza, Álvaro
Porras, Almudena
Gutiérrez-Neira, Carolina
Espinosa, Andrea
Onecha, Víctor V.
Ibáñez, Paula
Sánchez-Tembleque, Víctor
Udías, José M.
Fraile, Luis M.
In vivo production of fluorine-18 in a chicken egg tumor model of breast cancer for proton therapy range verification
title In vivo production of fluorine-18 in a chicken egg tumor model of breast cancer for proton therapy range verification
title_full In vivo production of fluorine-18 in a chicken egg tumor model of breast cancer for proton therapy range verification
title_fullStr In vivo production of fluorine-18 in a chicken egg tumor model of breast cancer for proton therapy range verification
title_full_unstemmed In vivo production of fluorine-18 in a chicken egg tumor model of breast cancer for proton therapy range verification
title_short In vivo production of fluorine-18 in a chicken egg tumor model of breast cancer for proton therapy range verification
title_sort in vivo production of fluorine-18 in a chicken egg tumor model of breast cancer for proton therapy range verification
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056503/
https://www.ncbi.nlm.nih.gov/pubmed/35490180
http://dx.doi.org/10.1038/s41598-022-11037-7
work_keys_str_mv AT espanasamuel invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT sanchezparcerisadaniel invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT bragadopaloma invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT gutierrezuzquizaalvaro invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT porrasalmudena invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT gutierrezneiracarolina invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT espinosaandrea invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT onechavictorv invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT ibanezpaula invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT sancheztemblequevictor invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT udiasjosem invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification
AT fraileluism invivoproductionoffluorine18inachickeneggtumormodelofbreastcancerforprotontherapyrangeverification